<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37452024</PMID><DateCompleted><Year>2023</Year><Month>07</Month><Day>17</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>23</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2041-1723</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Jul</Month><Day>14</Day></PubDate></JournalIssue><Title>Nature communications</Title><ISOAbbreviation>Nat Commun</ISOAbbreviation></Journal><ArticleTitle>Chronic inflammation, neutrophil activity, and autoreactivity splits long COVID.</ArticleTitle><Pagination><StartPage>4201</StartPage><MedlinePgn>4201</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">4201</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41467-023-40012-7</ELocationID><Abstract><AbstractText>While immunologic correlates of COVID-19 have been widely reported, their associations with post-acute sequelae of COVID-19 (PASC) remain less clear. Due to the wide array of PASC presentations, understanding if specific disease features associate with discrete immune processes and therapeutic opportunities is important. Here we profile patients in the recovery phase of COVID-19 via proteomics screening and machine learning to find signatures of ongoing antiviral B cell development, immune-mediated fibrosis, and markers of cell death in PASC patients but not in controls with uncomplicated recovery. Plasma and immune cell profiling further allow the stratification of PASC into inflammatory and non-inflammatory types. Inflammatory PASC, identifiable through a refined set of 12 blood markers, displays evidence of ongoing neutrophil activity, B cell memory alterations, and building autoreactivity more than a year post COVID-19. Our work thus helps refine PASC categorization to aid in both therapeutic targeting and epidemiological investigation of PASC.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Woodruff</LastName><ForeName>Matthew C</ForeName><Initials>MC</Initials><Identifier Source="ORCID">0000-0002-5252-7539</Identifier><AffiliationInfo><Affiliation>Department of Medicine, Division of Rheumatology, Lowance Center for Human Immunology, Emory University, Atlanta, GA, USA. mcwoodr@emory.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Emory Autoimmunity Center of Excellence, Emory University, Atlanta, GA, USA. mcwoodr@emory.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Bonham</LastName><ForeName>Kevin S</ForeName><Initials>KS</Initials><AffiliationInfo><Affiliation>Department of Biological Sciences, Wellesley College, Wellesley, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Anam</LastName><ForeName>Fabliha A</ForeName><Initials>FA</Initials><AffiliationInfo><Affiliation>Department of Medicine, Division of Rheumatology, Lowance Center for Human Immunology, Emory University, Atlanta, GA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Emory Autoimmunity Center of Excellence, Emory University, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Walker</LastName><ForeName>Tiffany A</ForeName><Initials>TA</Initials><Identifier Source="ORCID">0000-0002-9602-3754</Identifier><AffiliationInfo><Affiliation>Department of Medicine, Division of General Internal Medicine, Emory University, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Faliti</LastName><ForeName>Caterina E</ForeName><Initials>CE</Initials><Identifier Source="ORCID">0000-0003-0487-1914</Identifier><AffiliationInfo><Affiliation>Department of Medicine, Division of Rheumatology, Lowance Center for Human Immunology, Emory University, Atlanta, GA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Emory Autoimmunity Center of Excellence, Emory University, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ishii</LastName><ForeName>Yusho</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Medicine, Division of Rheumatology, Lowance Center for Human Immunology, Emory University, Atlanta, GA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Emory Autoimmunity Center of Excellence, Emory University, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaminski</LastName><ForeName>Candice Y</ForeName><Initials>CY</Initials><Identifier Source="ORCID">0000-0001-7564-1046</Identifier><AffiliationInfo><Affiliation>School of Medicine, Emory University, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ruunstrom</LastName><ForeName>Martin C</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>Department of Medicine, Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, Emory University, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cooper</LastName><ForeName>Kelly Rose</ForeName><Initials>KR</Initials><AffiliationInfo><Affiliation>Department of Medicine, Division of Rheumatology, Lowance Center for Human Immunology, Emory University, Atlanta, GA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Emory Autoimmunity Center of Excellence, Emory University, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Truong</LastName><ForeName>Alexander D</ForeName><Initials>AD</Initials><AffiliationInfo><Affiliation>Department of Medicine, Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, Emory University, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dixit</LastName><ForeName>Adviteeya N</ForeName><Initials>AN</Initials><AffiliationInfo><Affiliation>Department of Medicine, Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, Emory University, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Han</LastName><ForeName>Jenny E</ForeName><Initials>JE</Initials><Identifier Source="ORCID">0000-0003-1103-3935</Identifier><AffiliationInfo><Affiliation>Department of Medicine, Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, Emory University, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ramonell</LastName><ForeName>Richard P</ForeName><Initials>RP</Initials><Identifier Source="ORCID">0000-0002-2385-0636</Identifier><AffiliationInfo><Affiliation>Department of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine, University of Pittsburgh, Pittsburgh, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haddad</LastName><ForeName>Natalie S</ForeName><Initials>NS</Initials><Identifier Source="ORCID">0000-0002-1348-3094</Identifier><AffiliationInfo><Affiliation>MicroB-plex, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rudolph</LastName><ForeName>Mark E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Exagen Inc., Vista, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yalavarthi</LastName><ForeName>Srilakshmi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Rheumatology, University of Michigan, Ann Arbor, MI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Betin</LastName><ForeName>Viktoria</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>ImmuneID Inc., Waltham, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Natoli</LastName><ForeName>Ted</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-0953-0206</Identifier><AffiliationInfo><Affiliation>ImmuneID Inc., Waltham, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Navaz</LastName><ForeName>Sherwin</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Rheumatology, University of Michigan, Ann Arbor, MI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jenks</LastName><ForeName>Scott A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Department of Medicine, Division of Rheumatology, Lowance Center for Human Immunology, Emory University, Atlanta, GA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Emory Autoimmunity Center of Excellence, Emory University, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zuo</LastName><ForeName>Yu</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Division of Rheumatology, University of Michigan, Ann Arbor, MI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Knight</LastName><ForeName>Jason S</ForeName><Initials>JS</Initials><Identifier Source="ORCID">0000-0003-0995-9771</Identifier><AffiliationInfo><Affiliation>Division of Rheumatology, University of Michigan, Ann Arbor, MI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khosroshahi</LastName><ForeName>Arezou</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Medicine, Division of Rheumatology, Lowance Center for Human Immunology, Emory University, Atlanta, GA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Emory Autoimmunity Center of Excellence, Emory University, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>F Eun-Hyung</ForeName><Initials>FE</Initials><Identifier Source="ORCID">0000-0002-6133-5942</Identifier><AffiliationInfo><Affiliation>Department of Medicine, Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, Emory University, Atlanta, GA, USA. F.E.Lee@emory.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sanz</LastName><ForeName>Ignacio</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0003-4182-587X</Identifier><AffiliationInfo><Affiliation>Department of Medicine, Division of Rheumatology, Lowance Center for Human Immunology, Emory University, Atlanta, GA, USA. Ignacio.sanz@emory.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Emory Autoimmunity Center of Excellence, Emory University, Atlanta, GA, USA. Ignacio.sanz@emory.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>T32 HL116271</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AI125180</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K08 AR080205</GrantID><Acronym>AR</Acronym><Agency>NIAMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 CA260563</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002378</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>INV-002351</GrantID><Acronym>GATES</Acronym><Agency>Bill &amp; Melinda Gates Foundation</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AI110483</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 AI141993</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 AI049660</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>07</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Commun</MedlineTA><NlmUniqueID>101528555</NlmUniqueID><ISSNLinking>2041-1723</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009504" MajorTopicYN="Y">Neutrophils</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Dr. Lee is the founder of MicroB-plex, Inc and has research grants with Genentech. Dr. Mark Rudolph is employed by Exagen, Inc. Drs. Viktoria Betin and Ted Natoli are employed by ImmuneID Inc. The remaining authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>6</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>7</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>7</Month><Day>17</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>7</Month><Day>15</Day><Hour>10</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>7</Month><Day>14</Day><Hour>23</Hour><Minute>14</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>7</Month><Day>14</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37452024</ArticleId><ArticleId IdType="pmc">PMC10349085</ArticleId><ArticleId IdType="doi">10.1038/s41467-023-40012-7</ArticleId><ArticleId IdType="pii">10.1038/s41467-023-40012-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Brodin P. Immune determinants of COVID-19 disease presentation and severity. Nat. Med. 2021;27:28&#x2013;33. doi: 10.1038/s41591-020-01202-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-01202-8</ArticleId><ArticleId IdType="pubmed">33442016</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Q, Bastard P, Effort CHG, Cobat A, Casanova JL. Human genetic and immunological determinants of critical COVID-19 pneumonia. Nature. 2022;603:587&#x2013;598. doi: 10.1038/s41586-022-04447-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04447-0</ArticleId><ArticleId IdType="pmc">PMC8957595</ArticleId><ArticleId IdType="pubmed">35090163</ArticleId></ArticleIdList></Reference><Reference><Citation>Gandhi RT, Lynch JB, Del Rio C. Mild or moderate Covid-19. N. Engl. J. Med. 2020;383:1757&#x2013;1766. doi: 10.1056/NEJMcp2009249.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMcp2009249</ArticleId><ArticleId IdType="pubmed">32329974</ArticleId></ArticleIdList></Reference><Reference><Citation>Siordia JA., Jr. Epidemiology and clinical features of COVID-19: a review of current literature. J. Clin. Virol. 2020;127:104357. doi: 10.1016/j.jcv.2020.104357.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcv.2020.104357</ArticleId><ArticleId IdType="pmc">PMC7195311</ArticleId><ArticleId IdType="pubmed">32305884</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Leon S, et al. More than 50 long-term effects of COVID-19: a systematic review and meta-analysis. Sci. Rep. 2021;11:16144. doi: 10.1038/s41598-021-95565-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-95565-8</ArticleId><ArticleId IdType="pmc">PMC8352980</ArticleId><ArticleId IdType="pubmed">34373540</ArticleId></ArticleIdList></Reference><Reference><Citation>Poudel AN, et al. Impact of Covid-19 on health-related quality of life of patients: A structured review. PLoS ONE. 2021;16:e0259164. doi: 10.1371/journal.pone.0259164.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0259164</ArticleId><ArticleId IdType="pmc">PMC8553121</ArticleId><ArticleId IdType="pubmed">34710173</ArticleId></ArticleIdList></Reference><Reference><Citation>Helmsdal G, et al. Long COVID in the long run-23-month follow-up study of persistent symptoms. Open Forum Infect. Dis. 2022;9:ofac270. doi: 10.1093/ofid/ofac270.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofac270</ArticleId><ArticleId IdType="pmc">PMC9308378</ArticleId><ArticleId IdType="pubmed">35891696</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y, et al. Multiple early factors anticipate post-acute COVID-19 sequelae. Cell. 2022;185:881&#x2013;895 e820. doi: 10.1016/j.cell.2022.01.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.01.014</ArticleId><ArticleId IdType="pmc">PMC8786632</ArticleId><ArticleId IdType="pubmed">35216672</ArticleId></ArticleIdList></Reference><Reference><Citation>Control, C. F. D. Post-COVID conditions: information for healthcare providers. https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/post-covid-conditions.html (2022).</Citation></Reference><Reference><Citation>Organization, W. H. Coronavirus disease (COVID-19): post COVID-19 condition. https://www.who.int/news-room/questions-and-answers/item/coronavirus-disease-(covid-19)-post-covid-19-condition (2021).</Citation></Reference><Reference><Citation>Mathew, D. et al. Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications. Science369, 10.1126/science.abc8511 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7402624</ArticleId><ArticleId IdType="pubmed">32669297</ArticleId></ArticleIdList></Reference><Reference><Citation>Arunachalam PS, et al. Systems biological assessment of immunity to mild versus severe COVID-19 infection in humans. Science. 2020;369:1210&#x2013;1220. doi: 10.1126/science.abc6261.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abc6261</ArticleId><ArticleId IdType="pmc">PMC7665312</ArticleId><ArticleId IdType="pubmed">32788292</ArticleId></ArticleIdList></Reference><Reference><Citation>Eddins DJ, et al. Transcriptional reprogramming of infiltrating neutrophils drives lung pathology in severe COVID-19 despite low viral load. Blood Adv. 2023;7:778&#x2013;799. doi: 10.1182/bloodadvances.2022008834.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/bloodadvances.2022008834</ArticleId><ArticleId IdType="pmc">PMC9906672</ArticleId><ArticleId IdType="pubmed">36399523</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuo, Y. et al. Neutrophil extracellular traps in COVID-19. JCI Insight5, 10.1172/jci.insight.138999 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7308057</ArticleId><ArticleId IdType="pubmed">32329756</ArticleId></ArticleIdList></Reference><Reference><Citation>Bange EM, et al. CD8(+) T cells contribute to survival in patients with COVID-19 and hematologic cancer. Nat. Med. 2021;27:1280&#x2013;1289. doi: 10.1038/s41591-021-01386-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01386-7</ArticleId><ArticleId IdType="pmc">PMC8291091</ArticleId><ArticleId IdType="pubmed">34017137</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaneko, N. et al. The loss of Bcl-6 expressing T follicular helper cells and the absence of germinal centers in COVID-19. Cell183, 143&#x2013;157 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7437499</ArticleId><ArticleId IdType="pubmed">32877699</ArticleId></ArticleIdList></Reference><Reference><Citation>Woodruff MC, et al. Extrafollicular B cell responses correlate with neutralizing antibodies and morbidity in COVID-19. Nat. Immunol. 2020;21:1506&#x2013;1516. doi: 10.1038/s41590-020-00814-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-020-00814-z</ArticleId><ArticleId IdType="pmc">PMC7739702</ArticleId><ArticleId IdType="pubmed">33028979</ArticleId></ArticleIdList></Reference><Reference><Citation>Jenks SA, et al. Distinct effector B cells induced by unregulated toll-like receptor 7 contribute to pathogenic responses in systemic lupus erythematosus. Immunity. 2018;49:725&#x2013;739.e726. doi: 10.1016/j.immuni.2018.08.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2018.08.015</ArticleId><ArticleId IdType="pmc">PMC6217820</ArticleId><ArticleId IdType="pubmed">30314758</ArticleId></ArticleIdList></Reference><Reference><Citation>Woodruff, M. C. et al. Dysregulated naive B cells and de novo autoreactivity in severe COVID-19. Nature10.1038/s41586-022-05273-0 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9630115</ArticleId><ArticleId IdType="pubmed">36044993</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein, J. et al. Distinguishing features of long COVID identified through immune profiling. Preprint at medRxiv10.1101/2022.08.09.22278592 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10620090</ArticleId><ArticleId IdType="pubmed">37748514</ArticleId></ArticleIdList></Reference><Reference><Citation>Merad M, Martin JC. Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages. Nat. Rev. Immunol. 2020;20:355&#x2013;362. doi: 10.1038/s41577-020-0331-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-020-0331-4</ArticleId><ArticleId IdType="pmc">PMC7201395</ArticleId><ArticleId IdType="pubmed">32376901</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen, L. Y. C., Hoiland, R. L., Stukas, S., Wellington, C. L. &amp; Sekhon, M. S. Confronting the controversy: interleukin-6 and the COVID-19 cytokine storm syndrome. Eur. Respir. J. 56, 10.1183/13993003.03006-2020 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7474149</ArticleId><ArticleId IdType="pubmed">32883678</ArticleId></ArticleIdList></Reference><Reference><Citation>Li L, et al. Interleukin-8 as a biomarker for disease prognosis of coronavirus disease-2019 patients. Front. Immunol. 2020;11:602395. doi: 10.3389/fimmu.2020.602395.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.602395</ArticleId><ArticleId IdType="pmc">PMC7820901</ArticleId><ArticleId IdType="pubmed">33488599</ArticleId></ArticleIdList></Reference><Reference><Citation>Kircheis R, et al. NF-kappaB pathway as a potential target for treatment of critical stage COVID-19 patients. Front. Immunol. 2020;11:598444. doi: 10.3389/fimmu.2020.598444.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.598444</ArticleId><ArticleId IdType="pmc">PMC7759159</ArticleId><ArticleId IdType="pubmed">33362782</ArticleId></ArticleIdList></Reference><Reference><Citation>Sneller MC, et al. A longitudinal study of COVID-19 sequelae and immunity: baseline findings. Ann. Intern. Med. 2022;175:969&#x2013;979. doi: 10.7326/M21-4905.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M21-4905</ArticleId><ArticleId IdType="pmc">PMC9128805</ArticleId><ArticleId IdType="pubmed">35605238</ArticleId></ArticleIdList></Reference><Reference><Citation>Volovici, V., Syn, N. L., Ercole, A., Zhao, J. J. &amp; Liu, N. Steps to avoid overuse and misuse of machine learning in clinical research. Nat. Med. 10.1038/s41591-022-01961-6 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">36097217</ArticleId></ArticleIdList></Reference><Reference><Citation>Dufner A, et al. The ubiquitin-specific protease USP8 is critical for the development and homeostasis of T cells. Nat. Immunol. 2015;16:950&#x2013;960. doi: 10.1038/ni.3230.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni.3230</ArticleId><ArticleId IdType="pubmed">26214742</ArticleId></ArticleIdList></Reference><Reference><Citation>Ray PR, et al. A pharmacological interactome between COVID-19 patient samples and human sensory neurons reveals potential drivers of neurogenic pulmonary dysfunction. Brain Behav. Immun. 2020;89:559&#x2013;568. doi: 10.1016/j.bbi.2020.05.078.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2020.05.078</ArticleId><ArticleId IdType="pmc">PMC7263237</ArticleId><ArticleId IdType="pubmed">32497778</ArticleId></ArticleIdList></Reference><Reference><Citation>McFarland AJ, Yousuf MS, Shiers S, Price TJ. Neurobiology of SARS-CoV-2 interactions with the peripheral nervous system: implications for COVID-19 and pain. Pain. Rep. 2021;6:e885. doi: 10.1097/PR9.0000000000000885.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/PR9.0000000000000885</ArticleId><ArticleId IdType="pmc">PMC7803673</ArticleId><ArticleId IdType="pubmed">33458558</ArticleId></ArticleIdList></Reference><Reference><Citation>Odell ID, et al. Epiregulin is a dendritic cell-derived EGFR ligand that maintains skin and lung fibrosis. Sci. Immunol. 2022;7:eabq6691. doi: 10.1126/sciimmunol.abq6691.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abq6691</ArticleId><ArticleId IdType="pmc">PMC9840167</ArticleId><ArticleId IdType="pubmed">36490328</ArticleId></ArticleIdList></Reference><Reference><Citation>Haddad NS, et al. One-stop serum assay identifies COVID-19 disease severity and vaccination responses. Immunohorizons. 2021;5:322&#x2013;335. doi: 10.4049/immunohorizons.2100011.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/immunohorizons.2100011</ArticleId><ArticleId IdType="pmc">PMC9190970</ArticleId><ArticleId IdType="pubmed">34001652</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramaswamy A, et al. Immune dysregulation and autoreactivity correlate with disease severity in SARS-CoV-2-associated multisystem inflammatory syndrome in children. Immunity. 2021;54:1083&#x2013;1095.e1087. doi: 10.1016/j.immuni.2021.04.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2021.04.003</ArticleId><ArticleId IdType="pmc">PMC8043654</ArticleId><ArticleId IdType="pubmed">33891889</ArticleId></ArticleIdList></Reference><Reference><Citation>Harada M, et al. Temporal expression of growth factors triggered by epiregulin regulates inflammation development. J. Immunol. 2015;194:1039&#x2013;1046. doi: 10.4049/jimmunol.1400562.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1400562</ArticleId><ArticleId IdType="pubmed">25556244</ArticleId></ArticleIdList></Reference><Reference><Citation>Mutua V, Gershwin LJ. A review of neutrophil extracellular traps (NETs) in disease: potential anti-NETs therapeutics. Clin. Rev. Allergy Immunol. 2021;61:194&#x2013;211. doi: 10.1007/s12016-020-08804-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12016-020-08804-7</ArticleId><ArticleId IdType="pmc">PMC7395212</ArticleId><ArticleId IdType="pubmed">32740860</ArticleId></ArticleIdList></Reference><Reference><Citation>Bramante, C. et al. Outpatient treatment of COVID-19 and the development of long COVID over 10 months: a multi-center, quadruple-blind, parallel group randomized phase 3 trial. Lancet10.2139/ssrn.4375620 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11259948</ArticleId><ArticleId IdType="pubmed">37302406</ArticleId></ArticleIdList></Reference><Reference><Citation>Pretorius E, et al. Persistent clotting protein pathology in long COVID/Post-acute sequelae of COVID-19 (PASC) is accompanied by increased levels of antiplasmin. Cardiovasc. Diabetol. 2021;20:172. doi: 10.1186/s12933-021-01359-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12933-021-01359-7</ArticleId><ArticleId IdType="pmc">PMC8381139</ArticleId><ArticleId IdType="pubmed">34425843</ArticleId></ArticleIdList></Reference><Reference><Citation>Chatzidionysiou K, et al. Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries. Ann. Rheum. Dis. 2011;70:1575&#x2013;1580. doi: 10.1136/ard.2010.148759.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.2010.148759</ArticleId><ArticleId IdType="pubmed">21571731</ArticleId></ArticleIdList></Reference><Reference><Citation>Swank, Z. et al. Persistent circulating SARS-CoV-2 spike is associated with post-acute COVID-19 sequelae. Clin. Infect. Dis.10.1093/cid/ciac722 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10169416</ArticleId><ArticleId IdType="pubmed">36052466</ArticleId></ArticleIdList></Reference><Reference><Citation>Assarsson E, et al. Homogenous 96-plex PEA immunoassay exhibiting high sensitivity, specificity, and excellent scalability. PLoS ONE. 2014;9:e95192. doi: 10.1371/journal.pone.0095192.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0095192</ArticleId><ArticleId IdType="pmc">PMC3995906</ArticleId><ArticleId IdType="pubmed">24755770</ArticleId></ArticleIdList></Reference><Reference><Citation>Shrock, E. L., Shrock, C. L. &amp; Elledge, S. J. VirScan: high-throughput profiling of antiviral antibody epitopes. Bio. Protoc. 12, 10.21769/BioProtoc.4464 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9303818</ArticleId><ArticleId IdType="pubmed">35937932</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>